SYK Stock Analysis: Stryker | NYSE
Medical Devices | NYSE, USA | Market Cap: 108.379m USD | 12M Return: -19.8% | US8636671013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 683M
EPS Trend: 98.7%
Qual. Beats: 1
Rev. Trend: 99.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stryker Corporation (NYSE: SYK) is a U.S.-based medical technology company founded in 1941 and headquartered in Portage, Michigan, operating through two main segments: MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment provides surgical equipment, navigation systems, endoscopy and communications platforms, emergency and intensive care products, stroke treatment devices, and orthobiologic products. The Orthopaedics segment supplies implants for hip, knee, shoulder, ankle, and trauma procedures, along with the Mako robotic-assisted surgery platform, including its Mako Shoulder application. Stryker distributes its products through company-owned subsidiaries, branches, and third-party dealers across roughly 61 countries, serving doctors, hospitals, and other healthcare facilities.
The medical device industry is characterized by high regulatory approval barriers, long product development cycles, and strong relationships with surgeons and healthcare providers, which tend to support incumbent leaders like Stryker. Demand is largely driven by aging populations, rising surgical volumes, and growing adoption of robotic-assisted and minimally invasive procedures across both orthopedic and general surgery markets.
- Mako robotic system adoption drives orthopaedic revenue growth
- Hospital capital budget cuts pressure MedSurg equipment sales
- Acquisition pipeline expands neurotechnology and surgical portfolio
| Net Income: 3.73b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.12 > 1.0 |
| NWC/Revenue: 29.93% < 20% (prev 23.99%; Δ 5.94% < -1%) |
| CFO/TA 0.12 > 3% & CFO 5.53b > Net Income 3.73b |
| Net Debt (11.5b) to EBITDA (6.69b): 1.71 < 3 |
| Current Ratio: 2.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (386.0m) vs 12m ago -0.10% < -2% |
| Gross Margin: 65.17% > 18% (prev 62.87%; Δ 2.29% > 0.5%) |
| Asset Turnover: 54.82% > 50% (prev 51.41%; Δ 3.41% > 0%) |
| Interest Coverage Ratio: 6.59 > 6 (EBIT TTM 5.45b / Interest Expense TTM 827.0m) |
| A: 0.16 (Total Current Assets 14.4b - Total Current Liabilities 6.68b) / Total Assets 47.9b |
| B: 0.46 (Retained Earnings 21.8b / Total Assets 47.9b) |
| C: 0.12 (EBIT TTM 5.45b / Avg Total Assets 47.1b) |
| D: 1.00 (Book Value of Equity 24.0b / Total Liabilities 23.9b) |
| Altman-Z'' = 4.37 = AA |
| DSRI: 0.88 (Receivables 3.74b/3.92b, Revenue 25.8b/23.8b) |
| GMI: 0.96 (GM 62.87% / 65.17%) |
| AQI: 0.97 (AQ_t 0.61 / AQ_t-1 0.63) |
| SGI: 1.08 (Revenue 25.8b / 23.8b) |
| TATA: -0.04 (NI 3.73b - CFO 5.53b) / TA 47.9b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of October 16, 2026, the stock is trading at USD 293.23 with a total of 3,121,034 shares traded. Over the past week, the price has changed by +5.87%, over one month by +4.50%, over three months by -7.04% and over the past year by -19.82%.
Current recommended Stop Loss: 279.50 (which is 4.7% or 1.8 ATR below the current price).
Stryker has received a consensus analysts rating of 4.31. Therefore, it is recommended to buy SYK.
- StrongBuy: 15
- Buy: 8
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 362.6 | 23.7% |
P/E Trailing = 29.2798
P/E Forward = 16.4745
P/S = 4.1947
P/B = 4.3987
P/EG = 1.2877
Revenue TTM = 25.8b USD
EBIT TTM = 5.45b USD
EBITDA TTM = 6.69b USD
Long Term Debt = 14.2b USD (from longTermDebt, last quarter)
Short Term Debt = 750.0m USD (from shortTermDebt, last quarter)
Debt = 14.9b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.5b USD (calculated: Debt 14.9b - CCE 3.48b)
Enterprise Value = 120b USD (108b + Debt 14.9b - CCE 3.48b)
Interest Coverage Ratio = 6.59 (Ebit TTM 5.45b / Interest Expense TTM 827.0m)
EV/FCF = 25.49x (Enterprise Value 120b / FCF TTM 4.70b)
FCF Yield = 3.92% (FCF TTM 4.70b / Enterprise Value 120b)
FCF Margin = 18.20% (FCF TTM 4.70b / Revenue TTM 25.8b)
Net Margin = 14.43% (Net Income TTM 3.73b / Revenue TTM 25.8b)
Gross Margin = 65.17% ((Revenue TTM 25.8b - Cost of Revenue TTM 9.00b) / Revenue TTM)
Gross Margin QoQ = 68.27% (prev 63.29%)
Tobins Q-Ratio = 2.50 (Enterprise Value 120b / Total Assets 47.9b)
Interest Expense / Debt = 5.53% (Interest Expense 827.0m / Debt 14.9b)
Taxrate = 27.56% (1.42b / 5.15b)
NOPAT = 3.94b (EBIT 5.45b * (1 - 27.56%))
Current Ratio = 2.16 (Total Current Assets 14.4b / Total Current Liabilities 6.68b)
Debt / Equity = 0.62 (Debt 14.9b / totalStockholderEquity, last quarter 24.0b)
Debt / EBITDA = 1.71 (Net Debt 11.5b / EBITDA 6.69b)
Debt / FCF = 2.44 (Net Debt 11.5b / FCF TTM 4.70b)
Total Stockholder Equity = 22.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.91% (Net Income 3.73b / Total Assets 47.9b)
RoE = 16.36% (Net Income TTM 3.73b / Total Stockholder Equity 22.8b)
RoCE = 14.72% (EBIT 5.45b / Capital Employed (Equity 22.8b + L.T.Debt 14.2b))
RoIC = 9.69% (NOPAT 3.94b / Invested Capital 40.7b)
WACC = 6.44% (E(108b)/V(123b) * Re(6.77%) + D(14.9b)/V(123b) * Rd(5.53%) * (1-Tc(0.28)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 75.43 | Cagr: 0.10%
[DCF] Terminal Value 77.97% ; FCFF base≈4.43b ; Y1≈5.08b ; Y5≈7.48b
[DCF] Fair Price = 263.4 (EV 112b - Net Debt 11.5b = Equity 101b / Shares 383.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.75 | EPS CAGR: 12.24% | SUE: 1.38 | # QB: 1
Revenue Correlation: 99.77 | Revenue CAGR: 10.21% | SUE: 0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=3.56 | Chg30d=-0.77% | Revisions=-81% | Analysts=25
EPS current Year (2026-12-31): EPS=14.97 | Chg30d=-0.26% | Revisions=-69% | GrowthEPS=+9.8% | GrowthRev=+8.3%
EPS next Year (2027-12-31): EPS=16.69 | Chg30d=-0.30% | Revisions=-80% | GrowthEPS=+11.5% | GrowthRev=+8.6%
[Analyst] Revisions Ratio: -88% (up=1, down=37)